Alterations in fecal short-chain fatty acids in patients with irritable bowel syndrome: A systematic review and meta-analysis

Qinghua Sun, Qiong Jia, Lijin Song, Liping Duan, Qinghua Sun, Qiong Jia, Lijin Song, Liping Duan

Abstract

Background: Recent studies indicate that gut microbiota disorders potentially contribute to the pathogenesis of irritable bowel syndrome (IBS), which can be partly reflected by fecal short-chain fatty acids (SCFAs) generated from gut microbiota. Previous studies on SCFA alterations in patients with IBS have yielded conflicting results. No prior systematic review has been conducted on the alterations in fecal SCFAs in IBS patients.

Aims: We performed a meta-analysis to explore and clarify alterations in fecal SCFAs in IBS patients.

Methods: Case-control studies, randomized controlled trials (RCTs), and self-controlled studies were identified through electronic database searches. The standardized mean difference (SMD) with 95% confidence interval (CI) in fecal SCFA levels between different groups was calculated.

Results: The proportion of fecal propionate in patients with IBS was significantly higher than in healthy controls (HCs) (SMD = 0.44, 95% CI = 0.12, 0.76). A subgroup analysis showed that the concentration of fecal propionate (SMD = -0.91, 95% CI = -1.41, -0.41) and butyrate (SMD = -0.53, 95% CI = -1.01, -0.04) in patients with constipation-predominant IBS (IBS-C) was significantly lower than that in HCs, and the concentration of fecal butyrate in patients with diarrhea-predominant IBS (IBS-D) was higher than that in HCs (SMD = 0.34, 95% CI = 0.00, 0.67). Finally, we found that restricted diets correlated with fecal butyrate reduction in IBS (SMD = -0.26, 95% CI = -0.51, -0.01).

Conclusions: In terms of fecal SCFAs, there were differences between patients with IBS and HCs. In IBS-C patients, propionate and butyrate were reduced, whereas butyrate was increased in IBS-D patients in comparison to HCs. Propionate and butyrate could be used as biomarkers for IBS diagnosis.

Conflict of interest statement

No potential conflicts of interest relevant to this article were reported.

Figures

Figure 1
Figure 1
Flowchart of study selection. HC = healthy control, IBS = irritable bowel syndrome, RCT = randomized controlled trial, SCFA = short-chain fatty acids, SD = standard deviation.
Figure 2
Figure 2
Forest plots of alterations of fecal short-chain fatty acids in patients with irritable bowel syndrome versus healthy controls: (A-1) concentration of acetate, (A-2) proportion of acetate, (B-1) concentration of propionate, (B-2) proportion of propionate, (C-1) concentration of butyrate, (C-2) proportion of butyrate, (D-1) concentration of iso-butyrate, (D-2) proportion of iso-butyrate, (E-1) concentration of valerate, (E-2) proportion of valerate, (F-1) concentration of iso-valerate, and (F-2) proportion of iso-valerate. CI = confidence interval, SMD = standardized mean difference.
Figure 3
Figure 3
Forest plots of alterations of fecal short-chain fatty acids concentration in patients with different subtypes of irritable bowel syndrome (IBS) versus healthy controls (HC): (A-1) acetate in constipation-predominant irritable bowel syndrome (IBS-C) vs HC, (A-2) acetate in diarrhea-predominant irritable bowel syndrome (IBS-D) vs HC, (B-1) propionate in IBS-C vs HC, (B-2) propionate in IBS-D vs HC, (C-1) butyrate in IBS-C vs HC, and (C-2) butyrate in IBS-D vs HC. CI = confidence interval, SMD = standardized mean difference
Figure 4
Figure 4
Forest plots of alterations of fecal short-chain fatty acids concentration in patients with irritable bowel syndrome after different treatments: (A-1) acetate after restricted diet, (A-2) acetate after probiotics treatment, (B-1) propionate after restricted diet, (B-2) propionate after probiotics treatment, (C-1) butyrate after restricted diet, (C-2) butyrate after probiotics treatment, (D-1) iso-butyrate after restricted diet, (D-2) iso-butyrate after probiotics treatment, (E-1) valerate after restricted diet, (E-2) valerate after probiotics treatment, (F-1) iso-valerate after restricted diet, and (F-2) iso-valerate after probiotics treatment. CI = confidence interval, SMD = standardized mean difference.
Figure 5
Figure 5
Funnel plots of included studies analyzing the concentration of fecal short-chain fatty acids from patients with irritable bowel syndrome versus healthy controls: (A) acetate, (B) propionate, (C) butyrate. SE = standard error, SMD = standardized mean difference.

References

    1. Guthrie E, Creed F, Fernandes L, et al. Cluster analysis of symptoms and health seeking behaviour differentiates subgroups of patients with severe irritable bowel syndrome. Gut 2003;52:1616–22.
    1. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130:1377–90.
    1. Evangelista S. Benefits from long-term treatment in irritable bowel syndrome. Gastroenterol Res Pract 2012;2012:936960.
    1. Müller-Lissner S, Kamm MA, Musoglu A, et al. Safety, tolerability, and efficacy of tegaserod over 13 months in patients with chronic constipation. Am J Gastroenterol 2006;101:2558–69. quiz 2671.
    1. Müller-Lissner S, Holtmann G, Rueegg P, et al. Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2005;21:11–20.
    1. Ghoshal UC, Srivastava D. Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype. World J Gastroenterol 2014;20:2482–91.
    1. Kennedy PJ, Cryan JF, Dinan TG, et al. Irritable bowel syndrome: a microbiome-gut-brain axis disorder? World J Gastroenterol 2014;20:14105–25.
    1. Jeffery IB, O’Toole PW, Ohman L, et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012;61:997–1006.
    1. Tan J, McKenzie C, Potamitis M, et al. The role of short-chain fatty acids in health and disease. Adv Immunol 2014;121:91–119.
    1. Natarajan N, Pluznick JL. From microbe to man: the role of microbial short chain fatty acid metabolites in host cell biology. Am J Physiol Cell Physiol 2014;307:C979–85.
    1. Ahmed I, Greenwood R, Costello Bde L, et al. An investigation of fecal volatile organic metabolites in irritable bowel syndrome. PLoS One 2013;8:e58204.
    1. Velasquez-Manoff M. Gut microbiome: the peacekeepers. Nature 2015;518:S3–11.
    1. Vinolo MA, Rodrigues HG, Nachbar RT, et al. Regulation of inflammation by short chain fatty acids. Nutrients 2011;3:858–76.
    1. Weaver KR, Melkus GD, Henderson WA. Irritable bowel syndrome. Am J Nurs 2017;117:48–55.
    1. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA 2015;313:949–58.
    1. Anastasi JK, Capili B, Chang M. Managing irritable bowel syndrome. Am J Nurs 2013;113:42–52. quiz 54, 53.
    1. Gargari G, Taverniti V, Gardana C, et al. Fecal Clostridiales distribution and short-chain fatty acids reflect bowel habits in irritable bowel syndrome. Environ Microbiol 2018;20:3201–13.
    1. Farup PG, Rudi K, Hestad K. Faecal short-chain fatty acids – a diagnostic biomarker for irritable bowel syndrome? BMC Gastroenterol 2016;16:51.
    1. Ringel-Kulka T, Choi CH, Temas D, et al. Altered colonic bacterial fermentation as a potential pathophysiological factor in irritable bowel syndrome. Am J Gastroenterol 2015;110:1339–46.
    1. Tana C, Umesaki Y, Imaoka A, et al. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 2010;22:512–9. e114–5.
    1. Halmos EP, Christophersen CT, Bird AR, et al. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut 2015;64:93–100.
    1. Philpott H, Nandurkar S, Lubel J, et al. Alternative investigations for irritable bowel syndrome. J Gastroenterol Hepatol 2013;28:73–7.
    1. Kajander K, Krogius-Kurikka L, Rinttilä T, et al. Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome. Aliment Pharmacol Ther 2007;26:463–73.
    1. Higgins J, Green S. The Cochrane C, Cochrane Reviewers H. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. 2008.
    1. Walton C, Fowler DP, Turner C, et al. Analysis of volatile organic compounds of bacterial origin in chronic gastrointestinal diseases. Inflamm Bowel Dis 2013;19:2069–78.
    1. Cremon C, Guglielmetti S, Gargari G, et al. Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. United European Gastroenterol J 2018;6:604–13.
    1. Treem WR, Ahsan N, Kastoff G, et al. Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation. J Pediatr Gastroenterol Nutr 1996;23:280–6.
    1. Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014;14:135.
    1. Chassard C, Dapoigny M, Scott KP, et al. Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment Pharmacol Ther 2012;35:828–38.
    1. Valeur J, Morken MH, Norin E, et al. Intestinal fermentation in patients with self-reported food hypersensitivity: painful, but protective? Clin Exp Gastroenterol 2010;3:65–70.
    1. Vernia P, Latella G, Magliocca FM. Seeking clues for a positive diagnosis of the irritable bowel syndrome. Eur J Clin Invest 1987;17:189–93.
    1. Eastwood MA, Walton BA, Brydon WG, et al. Faecal weight, constituents, colonic motility, and lactose tolerance in the irritable bowel syndrome. Digestion 1984;30:7–12.
    1. Valeur J, Røseth AG, Knudsen T, et al. Fecal fermentation in irritable bowel syndrome: influence of dietary restriction of fermentable oligosaccharides, disaccharides, monosaccharides and polyols. Digestion 2016;94:50–6.
    1. Acosta A, Camilleri M, Shin A, et al. Effects of rifaximin on transit, permeability, fecal microbiome, and organic acid excretion in irritable bowel syndrome. Clin Transl Gastroenterol 2016;7:e173.
    1. Quigley EM, Fried M, Gwee KA, et al. World Gastroenterology Organisation Global Guidelines Irritable Bowel Syndrome: A Global Perspective Update September 2015. J Clin Gastroenterol 2016;50:704–13.
    1. Hustoft TN, Hausken T, Ystad SO, et al. Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome. Neurogastroenterol Motil 2017;29:e12969.
    1. Staudacher HM, Lomer MC, Anderson JL, et al. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr 2012;142:1510–8.
    1. Van den Abbeele P, Belzer C, Goossens M, et al. Butyrate-producing Clostridium cluster XIVa species specifically colonize mucins in an in vitro gut model. ISME J 2013;7:949–61.
    1. Louis P, Flint HJ. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett 2009;294:1–8.
    1. Vital M, Howe AC, Tiedje JM. Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data. mBio 2014;5:e00889.
    1. Miquel S, Martín R, Rossi O, et al. Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol 2013;16:255–61.
    1. Tap J, Derrien M, Törnblom H, et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology 2017;152:111–23. e8.
    1. Hayashi H, Sakamoto M, Kitahara M, et al. Diversity of the Clostridium coccoides group in human fecal microbiota as determined by 16S rRNA gene library. FEMS Microbiol Lett 2006;257:202–7.
    1. Gobert AP, Sagrestani G, Delmas E, et al. The human intestinal microbiota of constipated-predominant irritable bowel syndrome patients exhibits anti-inflammatory properties. Sci Rep 2016;6:39399.
    1. Fukumoto S, Tatewaki M, Yamada T, et al. Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. Am J Physiol Regul Integr Comp Physiol 2003;284:R1269–76.
    1. Rivière A, Selak M, Lantin D, et al. Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut. Front Microbiol 2016;7:979.
    1. Panzer AR, Lynch SV. Influence and effect of the human microbiome in allergy and asthma. Curr Opin Rheumatol 2015;27:373–80.
    1. Qin X, Sheth SU, Sharpe SM, et al. The mucus layer is critical in protecting against ischemia-reperfusion-mediated gut injury and in the restitution of gut barrier function. Shock 2011;35:275–81.
    1. Tran CD, Grice DM, Wade B, et al. Gut permeability, its interaction with gut microflora and effects on metabolic health are mediated by the lymphatics system, liver and bile acid. Future Microbiol 2015;10:1339–53.
    1. Tazoe H, Otomo Y, Kaji I, et al. Roles of short-chain fatty acids receptors, GPR41 and GPR43 on colonic functions. J Physiol Pharmacol 2008;59Suppl 2:251–62.
    1. Durbán A, Abellán JJ, Jimenéz-Hernández N, et al. Structural alterations of faecal and mucosa-associated bacterial communities in irritable bowel syndrome. Environ Microbiol Rep 2012;4:242–7.
    1. Carroll IM, Ringel-Kulka T, Siddle JP, et al. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2012;24:521–30. e248.
    1. Speranza E, Cioffi I, Santarpia L, et al. Fecal short chain fatty acids and dietary intake in Italian women with restrictive anorexia nervosa: a pilot study. Front Nutr 2018;5:119.
    1. Mayengbam S, Lambert JE, Parnell JA, et al. Impact of dietary fiber supplementation on modulating microbiota-host-metabolic axes in obesity. J Nutr Biochem 2018;64:228–36.
    1. Ford AC, Lacy BE, Talley NJ. Irritable bowel syndrome. N Engl J Med 2017;376:2566–78.
    1. Boesmans L, Valles-Colomer M, Wang J, et al. Butyrate producers as potential next-generation probiotics: safety assessment of the administration of Butyricicoccus pullicaecorum to healthy volunteers. mSystems 2018;3: e00094-18.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner